nach oben

Tumor Biology

Erschienen in:

16.09.2016 | Original Article

Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer

verfasst von: Li Ma, Lili Yuan, Jing An, Michelle C. Barton, Qingyuan Zhang, Zhaoliang Liu

Erschienen in: Tumor Biology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Acetylated H3 lysine 23 (H3K23ac) is a specific histone post-translational modification recognized by oncoprotein TRIM24. However, it is not clear whether H3K23ac levels are correlated with TRIM24 expression and what role H3K23ac may have in cancer. In this study, we collected breast carcinoma samples from 121 patients and conducted immunohistochemistry to determine the levels of TRIM24 and H3K23ac in breast cancer. Our results demonstrated that TRIM24 expression is positively correlated with H3K23ac levels, and high levels of both TRIM24 and H3K23ac predict shorter overall survival of breast cancer patients. We also showed that both TRIM24 and H3K23ac are higher in HER2-positive patients, and their levels were positively correlated with HER2 levels in breast cancer. Moreover, TRIM24 expression is associated with estrogen receptor (ER) and progesterone receptor (PR) statuses in both our cohort and The Cancer Genome Atlas (TCGA) breast carcinoma. In summary, our results revealed an important role of TRIM24 and H3K23ac in breast cancer and provided further evidence that TRIM24 small-molecule inhibitors may benefit ER- and PR-negative or HER2-positive breast cancer patients.

Tsai WW, Wang Z, Yiu TT, Akdemir KC, Xia W, Winter S, et al. TRIM24 links a non-canonical histone signature to breast cancer. Nature. 2010;468(7326):927–32. doi:10.1038/nature09542.CrossRefPubMedPubMedCentral

Chambon M, Orsetti B, Berthe ML, Bascoul-Mollevi C, Rodriguez C, Duong V, et al. Prognostic significance of TRIM24/TIF-1alpha gene expression in breast cancer. Am J Pathol. 2011;178(4):1461–9. doi:10.1016/j.ajpath.2010.12.026.CrossRefPubMedPubMedCentral

Li H, Sun L, Tang Z, Fu L, Xu Y, Li Z, et al. Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer. PLoS One. 2012;7(5):e37657. doi:10.1371/journal.pone.0037657.CrossRefPubMedPubMedCentral

Cui Z, Cao W, Li J, Song X, Mao L, Chen W. TRIM24 overexpression is common in locally advanced head and neck squamous cell carcinoma and correlates with aggressive malignant phenotypes. PLoS One. 2013;8(5):e63887. doi:10.1371/journal.pone.0063887.CrossRefPubMedPubMedCentral

Liu X, Huang Y, Yang D, Li X, Liang J, Lin L, et al. Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma. PLoS One. 2014;9(1):e85462. doi:10.1371/journal.pone.0085462.CrossRefPubMedPubMedCentral

Miao ZF, Wang ZN, Zhao TT, YY X, JH W, Liu XY, et al. TRIM24 is upregulated in human gastric cancer and promotes gastric cancer cell growth and chemoresistance. Virchows Arch. 2015;466(5):525–32. doi:10.1007/s00428-015-1737-4.CrossRefPubMed

Xue D, Zhang X, Liu J, Li N, Liu C, Liu Y, et al. Clinical significance and biological roles of TRIM24 in human bladder carcinoma. Tumour Biol. 2015. doi:10.1007/s13277-015-3393-3.

Zhang LH, Yin AA, Cheng JX, Huang HY, Li XM, Zhang YQ, et al. TRIM24 promotes glioma progression and enhances chemoresistance through activation of the PI3K/Akt signaling pathway. Oncogene. 2015;34(5):600–10. doi:10.1038/onc.2013.593.CrossRefPubMed

Pathiraja TN, Thakkar KN, Jiang S, Stratton S, Liu Z, Gagea M, et al. TRIM24 links glucose metabolism with transformation of human mammary epithelial cells. Oncogene. 2015;34(22):2836–45. doi:10.1038/onc.2014.220.CrossRefPubMed

10.

Jain AK, Allton K, Duncan AD, Barton MC. TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated phosphorylation and autodegradation during DNA damage. Mol Cell Biol. 2014;34(14):2695–709. doi:10.1128/MCB.01705-12.CrossRefPubMedPubMedCentral

11.

Herquel B, Ouararhni K, Davidson I. The TIF1alpha-related TRIM cofactors couple chromatin modifications to transcriptional regulation, signaling and tumor suppression. Transcription. 2011;2(5):231–6. doi:10.4161/trns.2.5.17725.CrossRefPubMedPubMedCentral

12.

Allton K, Jain AK, Herz HM, Tsai WW, Jung SY, Qin J, et al. TRIM24 targets endogenous p53 for degradation. Proc Natl Acad Sci U S A. 2009;106(28):11612–6. doi:10.1073/pnas.0813177106.CrossRefPubMedPubMedCentral

13.

Yondola MA. Hearing P. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J Virol. 2007;81(8):4264–71. doi:10.1128/JVI.02629-06.CrossRefPubMedPubMedCentral

14.

Peng H, Feldman I, Rauscher 3rd FJ. Hetero-oligomerization among the TIF family of RBCC/TRIM domain-containing nuclear cofactors: a potential mechanism for regulating the switch between coactivation and corepression. J Mol Biol. 2002;320(3):629–44. doi:10.1016/S0022-2836(02)00477-1.CrossRefPubMed

15.

Le Douarin B, Nielsen AL, Garnier JM, Ichinose H, Jeanmougin F, Losson R, et al. A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors. EMBO J. 1996;15(23):6701–15.PubMedPubMedCentral

16.

Le Douarin B, Zechel C, Garnier JM, Lutz Y, Tora L, Pierrat P, et al. The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J. 1995;14(9):2020–33.PubMedPubMedCentral

17.

Zennaro MC, Souque A, Viengchareun S, Poisson E, Lombes MA. New human MR splice variant is a ligand-independent transactivator modulating corticosteroid action. Mol Endocrinol. 2001;15(9):1586–98. doi:10.1210/mend.15.9.0689.CrossRefPubMed

18.

Kikuchi M, Okumura F, Tsukiyama T, Watanabe M, Miyajima N, Tanaka J, et al. TRIM24 mediates ligand-dependent activation of androgen receptor and is repressed by a bromodomain-containing protein, BRD7, in prostate cancer cells. Biochim Biophys Acta. 2009;1793(12):1828–36. doi:10.1016/j.bbamcr.2009.11.001.CrossRefPubMed

19.

Bodai L, Zsindely N, Gaspar R, Kristo I, Komonyi O, Boros IM. Ecdysone induced gene expression is associated with acetylation of histone H3 lysine 23 in Drosophila melanogaster. PLoS One. 2012;7(7):e40565. doi:10.1371/journal.pone.0040565.CrossRefPubMedPubMedCentral

20.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095.CrossRefPubMed

21.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.2004088.CrossRefPubMedPubMedCentral

22.

Reiner A, Spona J, Reiner G, Schemper M, Kolb R, Kwasny W, et al. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Am J Pathol. 1986;125(3):443–9.PubMedPubMedCentral

23.

Li B, Dewey CNRSEM. Accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. doi:10.1186/1471-2105-12-323.CrossRefPubMedPubMedCentral

24.

Khetchoumian K, Teletin M, Tisserand J, Mark M, Herquel B, Ignat M, et al. Loss of TRIM24 (TIF1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat Genet. 2007;39(12):1500–6. doi:10.1038/ng.2007.15.CrossRefPubMed

25.

Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci. 2014;4:45. doi:10.1186/2045-3701-4-45.CrossRefPubMedPubMedCentral

26.

Ferri E, Petosa C, McKenna CE. Bromodomains: structure, function and pharmacology of inhibition. Biochem Pharmacol. 2015. doi:10.1016/j.bcp.2015.12.005.PubMed

27.

Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, et al. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics. 2015;7(2):215–35. doi:10.2217/epi.14.73.CrossRefPubMed

28.

Bennett J, Fedorov O, Tallant C, Monteiro O, Meier J, Gamble V, et al. Discovery of a chemical tool inhibitor targeting the bromodomains of TRIM24 and BRPF. J Med Chem. 2015. doi:10.1021/acs.jmedchem.5b00458.

29.

Palmer WS, Poncet-Montange G, Liu G, Petrocchi A, Reyna N, Subramanian G, et al. Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor. J Med Chem. 2015. doi:10.1021/acs.jmedchem.5b00405.

30.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 1.2016. J Natl Compr Cancer Netw. 2015;13(12):1475–85.

Titel: Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer
verfasst von: Li Ma
Lili Yuan
Jing An
Michelle C. Barton
Qingyuan Zhang
Zhaoliang Liu
Publikationsdatum: 16.09.2016
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 11/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-5344-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Histone H3 lysine 23 acetylation is associated with oncogene TRIM24 expression and a poor prognosis in breast cancer

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

NETs in cancer

Upregulation of miR-192 inhibits cell growth and invasion and induces cell apoptosis by targeting TCF7 in human osteosarcoma

HOX genes: potential candidates for the progression of laryngeal squamous cell carcinoma

Hepatitis C virus promotes hepatocellular carcinogenesis by targeting TIPE2, a new regulator of DNA damage response

IL-13 receptor α2 stimulates human glioma cell growth and metastasis through the Src/PI3K/Akt/mTOR signaling pathway

Aberrant microRNA expression in tumor mycosis fungoides

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie